Literature DB >> 35312813

[Physical long-term consequences of cancer].

Lisa Ernst1, Georgia Schilling2,3.   

Abstract

The number of long-term survivors of malignant diseases is steadily increasing, which is due to the further development and optimization of multimodal therapy strategies and the mechanisms of new substance classes. These can now be combined with classical treatment methods or used sequentially. At the same time the number of patients who suffer from physical and psychosocial long-term consequences of cancer therapies or have to live with chronic side effects under the long-term therapies increases. Every therapy, whether radiation, chemotherapy, targeted therapy, or operation, has undesirable long-term side effects that contribute to the decrease of one's quality of life. These affect all parts of the body. As a result, patients can be heavily burdened. In oncology and in other disciplines involved in aftercare, these consequences must therefore be increasingly addressed and clarified and treatment strategies further developed. Unfortunately, there is still a considerable need for research in this area; moreover, there is a lack of clinical studies examining the evidence of a wide variety of holistic therapy methods.
© 2022. Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature.

Entities:  

Keywords:  Aftercare; Cancer survivorship; Long-term and late side effects; Multimodal cancer therapy; Tertiary preventive care

Mesh:

Year:  2022        PMID: 35312813     DOI: 10.1007/s00103-022-03504-3

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  32 in total

Review 1.  Late effects of cancer treatment: consequences for long-term brain cancer survivors.

Authors:  Montse Alemany; Roser Velasco; Marta Simó; Jordi Bruna
Journal:  Neurooncol Pract       Date:  2020-07-16

Review 2.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 3.  Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline.

Authors:  Larissa Nekhlyudov; Christina Lacchetti; Nancy B Davis; Thomas Q Garvey; David P Goldstein; J Chris Nunnink; Jose I Ruades Ninfea; Andrew L Salner; Talya Salz; Lillian L Siu
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544

Review 4.  Pulmonary toxicity of systemic lung cancer therapy.

Authors:  Kathryn Long; Karthik Suresh
Journal:  Respirology       Date:  2020-07-29       Impact factor: 6.424

5.  Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer.

Authors:  Aline Lima da Silva Deboni; Adelmo José Giordani; Nilza Nelly Fontana Lopes; Rodrigo Souza Dias; Roberto Araujo Segreto; Siri Beier Jensen; Helena Regina Comodo Segreto
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

Review 6.  Chemotherapy-induced lung disease.

Authors:  Andrew H Limper
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

Review 7.  Long-Term and Latent Side Effects of Specific Cancer Types.

Authors:  Nana Gegechkori; Lindsay Haines; Jenny J Lin
Journal:  Med Clin North Am       Date:  2017-08-02       Impact factor: 5.456

8.  Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.

Authors:  Debra L Laskin; Rama Malaviya; Jeffrey D Laskin
Journal:  Toxicol Sci       Date:  2019-04-01       Impact factor: 4.849

Review 9.  Trends and advances in cancer survivorship research: challenge and opportunity.

Authors:  Noreen M Aziz; Julia H Rowland
Journal:  Semin Radiat Oncol       Date:  2003-07       Impact factor: 5.934

Review 10.  Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue.

Authors:  Theoharis C Theoharides; Christos Cholevas; Konstantinos Polyzoidis; Antonios Politis
Journal:  Biofactors       Date:  2021-04-12       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.